Yuguero Oriol, Companys Maria, Guzmán Marianela, Maciel Rita, Llobet Cecília, López Aurora, Olles Rebeca, Pujol Violant, Ruiz Maria José, Saura Mireia, Vidal Carmel, Godoy Pere
ER LAB, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain.
Faculty of Medicine, University of Lleida, Lleida, Spain.
SAGE Open Med. 2022 Jun 27;10:20503121221108556. doi: 10.1177/20503121221108556. eCollection 2022.
We aimed to assess the prevalence and clinical characteristics of SARS-CoV-2 reinfections in a Spanish region.
This is a retrospective observational study in all patients with SARS-CoV-2 infections in the Lleida health region from 1 March to 30 November 2020. Reinfections were classified as patients with positive SARS-CoV-2 PCR tests separated by at least 90 days plus a negative test result between both infection episodes. Primary and secondary outcomes: The primary outcome was the percentage of SARS-CoV-2 reinfections among all SARS-CoV-2 infections detected during our study period. Secondary outcomes were the clinical and sociodemographic characteristics of patients with SARS-CoV-2 reinfections.
Of the 27,758 patients diagnosed with SARS-CoV-2 infection in the study period, 14 were identified as coronavirus reinfection (0.050%). Of the reinfected sample, 12 patients (85.7%) were women. The median age was 41.5 years. Two patients died in the second coronavirus episode.
The reinfection rate of SARS-CoV-2 in the Spanish region Lleida was relatively low during the observational period in 2020 (less than 1%). These data are in line with the notion that previous SARS-CoV-2 infections may offer a significant protection by so called natural immunity.
我们旨在评估西班牙某地区新冠病毒再次感染的患病率及临床特征。
这是一项对2020年3月1日至11月30日莱里达卫生区所有新冠病毒感染患者进行的回顾性观察研究。再次感染被定义为新冠病毒PCR检测呈阳性且两次感染发作间隔至少90天，同时两次感染发作之间有一次检测结果为阴性的患者。主要和次要结局：主要结局是我们研究期间检测到的所有新冠病毒感染中新冠病毒再次感染的百分比。次要结局是新冠病毒再次感染患者的临床和社会人口学特征。
在研究期间诊断为新冠病毒感染的27758例患者中，有14例被确定为冠状病毒再次感染（0.050%）。在再次感染的样本中，12例患者（85.7%）为女性。中位年龄为41.5岁。两名患者在第二次冠状病毒发作时死亡。
2020年观察期内，西班牙莱里达地区新冠病毒的再次感染率相对较低（低于1%）。这些数据与先前新冠病毒感染可能通过所谓的自然免疫提供显著保护的观点一致。
